A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Advanced Breast Cancer
- Sponsor
- Chinese Academy of Medical Sciences
- Enrollment
- 4200
- Locations
- 19
- Primary Endpoint
- Survival status at 3 years
- Last Updated
- 9 years ago
Overview
Brief Summary
To study the epidemiological trends and characteristics for advanced breast cancer patients, to analyze these trends and report the results
Detailed Description
In this study, the investigators conducted a hospital-based retrospective clinical study, recruiting female advanced breast cancer patients from 14 tertiary hospitals at 7 classic geographic regions, to study the clinical epidemiologic characteristics of advanced breast cancer and the current standard of clinical diagnosis and treatment in order to provide references for standardized treatment therapy, and to improve the quality of life and prolong survival time. To study the epidemiological trends and characteristics for advanced BC patients, to analyze these trends and report the results. To learn about the current treatment therapy for advanced BC patients in different areas in China.To provide references for standardized treatment therapy, to improve the quality of patients' life and to prolong the survival time for the advanced BC patients.To assess the different treatment therapies for advanced BC with consideration of economic cost-effectiveness
Investigators
Binghe Xu
Professor
Chinese Academy of Medical Sciences
Eligibility Criteria
Inclusion Criteria
- •diagnosed as advanced breast cancer during Jan1st,2012-Dec31st,2014
- •complete with surgical pathology data, auxiliary treatment, there is a clear recurrence, transfer time, place, transfer of recurrence after treatment, and curative effect evaluation details.In any age, ethnic group cases.
Exclusion Criteria
- •no available medical record
Outcomes
Primary Outcomes
Survival status at 3 years
Time Frame: 3 years
percentage of patients still alive at 3 years
Secondary Outcomes
- PFS(3 years)
- Survival status at 5 years(3 years)